

AMENDMENTS TO THE CLAIMS

Claims 1 to 40 (Cancelled)

41. (Currently Amended) A method of identifying breast cancer cells that are either resistant or sensitive to inhibition of cellular proliferation by a protein tyrosine kinase inhibitor comprising the step of determining the expression profile of a gene expression product from at least one informative gene in a sample, wherein said at least one informative gene is EphA2, wherein increased expression of said gene expression product in said sample relative to a standard is indicative of sensitivity to inhibition of cellular proliferation by a protein tyrosine kinase inhibitor, while decreased expression of said gene expression product in said sample relative to a standard is indicative of resistance to inhibition of cellular proliferation by a protein tyrosine kinase inhibitor, and wherein said protein tyrosine kinase inhibitor is an inhibitor of: Src, Fgr, Fyn, Yes, Blk, Hck, Lck, Lyn, BCR-ABL, PDGFR, c-Kit, and EphA2 activity.

Claims 42 to 52 (Cancelled).